Rifaximin: beyond the traditional antibiotic activity (Q38237218)

31 August 2017

title

Rifaximin: beyond the traditional antibiotic activity (English)

1 reference

31 August 2017

0 references

Fiorella Calanni

1

1 reference

31 August 2017

Cecilia Renzulli

series ordinal

2

1 reference

31 August 2017

Miriam Barbanti

series ordinal

3

1 reference

31 August 2017

Giuseppe Claudio Viscomi

series ordinal

4

1 reference

31 August 2017

language of work or name

1 reference

6 August 2014

1 reference

The Journal of Antibiotics

31 August 2017

published in

1 reference

31 August 2017

volume

67

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

667-670

1 reference

Rifaximin: in vitro and in vivo antibacterial activity--a review

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

In vitro activity and fecal concentration of rifaximin after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Bile acids improve the antimicrobial effect of rifaximin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Biologic properties and clinical uses of rifaximin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Modulation of the fecal bile acid profile by gut microbiota in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Bacterial translocation: overview of mechanisms and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Pregnane X receptor as a target for treatment of inflammatory bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

inferred from DOI database lookup

7 January 2021

based on heuristic

Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

inferred from DOI database lookup

7 January 2021

based on heuristic

Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.106

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/JA.2014.106

1 reference

Dimensions Publication ID

31 August 2017

1038702683

0 references

1 reference